A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes - Wikidata - awgldk - TriplyDB

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

http://www.wikidata.org/entity/Q28282265

about

Cardiovascular outcome trials for anti-diabetes medication: A holy grail of drug development?Dipeptidyl Peptidase 4 Inhibitors and the Risk of Cardiovascular Disease in Patients with Type 2 Diabetes: A Tale of Three Studies Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease Glycemic variability and glycemic control in the acutely ill cardiac patient Profile of saxagliptin in the treatment of type 2 diabetes: focus on Japanese patients Safety of dipeptidyl peptidase 4 inhibitors: a perspective review Saxagliptin overview: special focus on safety and adverse effects Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials DPP-4 inhibitors and lipids: systematic review and meta-analysis.Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent.Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus.Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.Diabetes and cardiovascular risk: are dipeptidyl peptidase-4 inhibitors beneficial?Saxagliptin for type 2 diabetes Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes Management of diabetes across the course of disease: minimizing obesity-associated complications Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.Sitagliptin counteracts seasonal fluctuation of glycemic control Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus.The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes.Cardiovascular biology of the incretin system.The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study.The effect of sitagliptin on cardiovascular risk profile in Korean patients with type 2 diabetes mellitus: a retrospective cohort study Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs.Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus.Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors.Microvascular Outcomes in Patients with Type 2 Diabetes Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Study Using German Electronic Medical Records.Linagliptin as add-on therapy to insulin for patients with type 2 diabetes The dipeptidyl peptidase (DPP)-4 inhibitors for type 2 diabetes mellitus in challenging patient groups.Cardiovascular Safety of Incretin-Based Therapies in Type 2 Diabetes: Systematic Review of Integrated Analyses and Randomized Controlled Trials.Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.

P2860

Q26740247-5C175D0A-8353-4F9F-8DBB-61704D64F628 Q26777177-CBAAB7BB-F4EA-434B-96CB-59EFE3EBE7F0 Q26784211-C115EE8F-BD94-4841-90DE-2CD71945E97E Q26821994-95D4360E-6647-4375-A3A1-E007F55AD7AD Q26824239-057837FD-0E0B-49BB-9DC7-803B77012670 Q26863262-A2E22C83-5412-458A-9490-816FA32B2DFE Q28278863-92129F90-FD8A-46AF-9FC0-4A52921ECF2A Q28547367-710EEA9B-A820-47CC-8464-A85301996811 Q33801801-72102FCD-9572-4844-BDBF-AB601E994485 Q34116689-6CAC2ECA-2F85-418B-970F-30BB51A26C08 Q34128612-1AE0F2F8-62CD-4EC0-A8CB-4B0BBF9FF79E Q34133971-9B50FDEB-1405-4A28-B1C1-1C33A62C27D7 Q34239784-B844D747-69AD-4650-8D2A-FF01332D9A34 Q34454269-BB7BF3D6-5A38-43C8-A1BF-DD9220AB2C69 Q34612834-036FAD0E-6FBD-4B4E-859B-E225DA80DAB5 Q34620486-A1AE0232-BF11-4487-9515-D7A16CA6F756 Q35179865-936A9FA0-7486-4EC3-BEFB-63FDD96E80BF Q35574560-1C7FE59A-BEB5-4DA2-8F38-4B247E64AB7D Q35736564-28624E9C-E44D-4782-B6C4-259CDA724C07 Q35777074-4BA66F17-FC52-4B77-9013-CA1D6AE220FA Q36057071-AEF68EA6-02FD-4A24-ABBD-EEC39F20073F Q36139126-B4433041-283E-44C7-9115-5F117A508C6F Q36381927-90B82B5D-2B45-4606-A05F-B08CA85FB235 Q36484283-F53B1DB4-EB8B-474A-BC11-513F78B7FED2 Q36521262-80A7230B-F5B6-42E1-86D6-FDAD8E69B1CE Q36682246-3FCE4FF1-1FAA-413B-BF26-E351EE893707 Q36710078-42439FFE-6912-4FCB-83A8-CCF5E6C029A2 Q36783681-3ADECA09-4F79-4891-A730-7DA3244D2711 Q36792608-DA05B289-CB31-43EF-B3A3-58BAAC3DDEB1 Q36845055-E828272E-31B1-4B41-8F9F-846023B4E50F Q36883337-6F06245D-B755-45D7-9CDF-546509A8DA11 Q36907339-B6551502-3CA4-467A-A5E8-751D1A4DE979 Q37079289-7BB205C4-D651-43B0-9AA8-D01893C7B035 Q37239286-77E7B56E-EACE-4CE7-BC8B-3CA7F98D8459 Q37281205-6372B33D-D5DB-4A48-911D-9EC87BE59890 Q37502682-0E235632-B5CD-4A0B-A630-0E0A935511D3 Q37562586-B1A3CF88-71B1-4616-8F30-10705C74622F Q37568863-45A133D2-D5AC-4936-AB0C-EFAF4C041CDD Q37835612-8247F1DB-8E80-474F-BAC6-3876665EA7AE Q37837059-919E5072-884E-45C8-B99F-97D905D77D7B

P2860

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

http://www.wikidata.org/entity/Q28282265

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A systematic assessment of car ...... nt program for type 2 diabetes

@ast

A systematic assessment of car ...... nt program for type 2 diabetes

@en

A systematic assessment of car ...... nt program for type 2 diabetes

@nl

type

label

A systematic assessment of car ...... nt program for type 2 diabetes

@ast

A systematic assessment of car ...... nt program for type 2 diabetes

@en

A systematic assessment of car ...... nt program for type 2 diabetes

@nl

prefLabel

A systematic assessment of car ...... nt program for type 2 diabetes

@ast

A systematic assessment of car ...... nt program for type 2 diabetes

@en

A systematic assessment of car ...... nt program for type 2 diabetes

@nl

P1433

Q28282265-AC7E0C15-E5C4-4466-A4D2-328656CF59E7

P1476

Q28282265-D3D3FF91-8A60-4FB2-A7F3-74FC7AAD18FD

P2093

Q28282265-06A47072-D857-458C-AD77-06F61017D9F2

Q28282265-1E690861-D229-4C36-819F-7F952FEADBCA

Q28282265-26EA712E-5942-4A3E-B27E-CBBFC296A00F

Q28282265-29086C55-24A5-4E65-A6F0-EDB031938F41

Q28282265-6FDC0C7C-D374-4DD2-AF77-BBF61B57E504

Q28282265-7D7BF65F-41C0-4115-BC56-4217F8D47A13

Q28282265-9B69465B-D3F6-44B8-8171-46BB573F0FB5

Q28282265-E4237F67-B5EE-473D-A214-1A00DFED8347

P2860

Q28282265-0A781908-68F6-40D2-AECE-77BC34D4E4F4

Q28282265-0C8BD08E-2811-4AC8-813C-7D92E8095457

Q28282265-148242AF-CAB0-4094-B1C2-4255C8CE7AEB

Q28282265-14858680-70F2-49D6-94ED-45B8A7CFCBC4

Q28282265-168ADCF8-5C48-42B7-85ED-56FE81B376D6

Q28282265-1D0E0728-C63B-4452-9098-310426B23883

Q28282265-1FDA2E50-86A8-494D-A761-640BCF979F8C

Q28282265-20AE8E48-B5DD-4E38-9EAC-C3C497944F24

Q28282265-2323FA83-2D41-4C9B-94B8-8391A9A03F87

Q28282265-26C58D8B-620F-4634-B230-91D263BB1C31

P304

Q28282265-299BEF37-CE84-47B0-AE71-EB55322D4157

P31

Q28282265-F4C4D075-37BE-462C-B465-C2C03601A6B0

P3181

Q28282265-704A4A3F-9C08-40FD-81B1-83822D954C61

P356

Q28282265-8614647B-38CE-41C1-8638-6F328DA4B6B1

P407

Q28282265-90E91535-A73E-4D75-AB73-E3E67A139E2D

P433

Q28282265-AB67EE51-ACBD-493A-890A-F805A10A5FF8

P478

Q28282265-EF662806-09C6-4B58-AAD5-B18668CD825C

P50

Q28282265-AADFB9AB-AEB4-41B8-ADF7-D02E8EAC1CD8

P577

Q28282265-6FC31E17-C9A6-4D62-BF0C-A907E7BCE135

P698

Q28282265-8F5CC3F6-7ADC-4621-A401-28BB0BBF2FBE

P921

Q28282265-7FD24425-36C7-4A47-91D9-A9309CC11993

Q28282265-A5121782-C231-4B9B-9CE7-2D2D246A2A5F

P3181

P356

PGM.2010.05.2138

P1433

Postgraduate Medicine

P1476

A systematic assessment of car ...... nt program for type 2 diabetes

@en

P2093

Fred T Fiedorek

http://www.w3.org/2001/XMLSchema#string

John H Alexander

http://www.w3.org/2001/XMLSchema#string

Mark Donovan

http://www.w3.org/2001/XMLSchema#string

Niklas Berglind

http://www.w3.org/2001/XMLSchema#string

Robert Frederich

http://www.w3.org/2001/XMLSchema#string

Robert Wolf

http://www.w3.org/2001/XMLSchema#string

Roland Chen

http://www.w3.org/2001/XMLSchema#string

Susan Harris

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Effects of intensive glucose lowering in type 2 diabetes

10-year follow-up of intensive glucose control in type 2 diabetes

Glucose control and vascular complications in veterans with type 2 diabetes

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

P304

16-27

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1592017

http://www.w3.org/2001/XMLSchema#string

P356

10.3810/PGM.2010.05.2138

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth W Mahaffey

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20463410

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

type-2 diabetes